Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 4/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 8/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18351661 | 1.00 | PPARG (0.56) | PPARGMMEFOLH1NAALAD2ACE | |
| SCHEMBL3923887 | 1.00 | PPARG (0.56) | PPARGMMEFOLH1NAALAD2ACE | |
| Hydroquinone SCHEMBL28778306 | 0.97 | PPARG (0.56) | PPARGMMEFOLH1NAALAD2ACE | |
| SCHEMBL28789648 | 0.93 | PPARG (0.60) | PPARGMMEFOLH1NAALAD2ACE | |
| SCHEMBL28789647 | 0.93 | PPARG (0.60) | PPARGMMEFOLH1NAALAD2ACE | |
| SCHEMBL1533645 | 0.90 | PPARG (0.58) | PPARGMMEFOLH1NAALAD2 | |
| SCHEMBL1533647 | 0.90 | PPARG (0.58) | PPARGMMEFOLH1NAALAD2 | |
| SCHEMBL6250861 | 0.90 | PPARG (0.58) | PPARGMMEFOLH1NAALAD2 | |
| Phenylalanine SCHEMBL8974614 | 0.87 | SLC7A5 (0.65) | PPARGMMEACESLC7A5 | |
| SCHEMBL11276580 | 0.86 | MME (0.53) | PPARGMMEFOLH1NAALAD2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113293151-A | Short-chain dehydrogenase mutants and uses thereof | 沈阳药科大学 | 2021-08-24 | — | — | CN | claimed |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12216122-B2 | Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1) | REGENERON PHARMACEUTICALS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | disclosed |
| CN-115785124-A | KRAS G12D inhibitors and uses thereof | 润佳（苏州）医药科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
| CN-113293151-B | Short-chain dehydrogenase mutants and uses thereof | 沈阳药科大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-113293152-B | Short-chain dehydrogenase mutant and use thereof | 沈阳药科大学 | 2022-05-20 | — | — | CN | disclosed |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| CN-113293151-A | Short-chain dehydrogenase mutants and uses thereof | 沈阳药科大学 | 2021-08-24 | — | — | CN | disclosed |
| CN-113293152-A | Short-chain dehydrogenase mutants and uses thereof | 沈阳药科大学 | 2021-08-24 | — | — | CN | disclosed |
| CN-108570460-B | Short-chain dehydrogenase mutants and uses thereof | 沈阳药科大学 | 2021-07-30 | — | — | CN | disclosed |
| US-9534016-B2 | Netrin loop peptide mimetics and uses thereof | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2017-01-03 | — | — | US | disclosed |
| WO-2009009035-A1 | SOMATOSTATIN ANALOG AND USES THEREOF | IPSEN PHARMA S.A.S. (FR) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12216122-B2 | Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1) | IDO1, IDO2, KYNU | PPARG 4816/4885MME 287/4885FOLH1 101/4885 |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL17A, IL36G | PPARG 2233/4885MME 47/4885FOLH1 1213/4885 |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | PPARG 1731/4885MME 299/4885FOLH1 640/4885 |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | PPARG 1731/4885MME 299/4885FOLH1 640/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | PPARG 2135/4885MME 15/4885FOLH1 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.